Collaboration

#Antisense Oligonucleotides (ASOs) #Collaboration #Evotec #Partnership #Rare disease #SynaptixBio

SynaptixBio and Evotec extend rare disease therapies partnership

SynaptixBio and Evotec have announced they are extending their partnership to find further candidate drugs to treat H-ABC, the most severe form of TUBB4A leukodystrophy. The drug research was originally carried out by the Children’s Hospital of Philadelphia (CHOP), the world’s leading centre for leukodystrophy research,… Read More

#News

MRI of the brain
#Africa #Collaboration #epilepsy #LMICs #University of Oxford

Oxford centre to address global epilepsy challenges

The University of Oxford is launching The Centre for Global Epilepsy to address the global burden of epilepsy, particularly in lower-income countries. Based at Wolfson College, Oxford, the Centre for Global Epilepsy will collaborate with key research institutions and epilepsy clinics worldwide, linking expertise from high-income… Read More

#News

Human adenovirus
#AAV #Cell and gene therapy #Cell and Gene Therapy Catapult #Collaboration #Gene delivery

Cross-industry consortium to improve AAV formulation

The Cell and Gene Therapy Catapult (CGT Catapult) has established a cross-industry consortium to improve the understanding and process optimisation of adeno-associated virus (AAV) formulation. AAV-based gene therapies are being developed to treat a broad range of inherited and chronic diseases and several of these therapies have already… Read More

#News

#Collaboration #Evotec #France #Infectious diseases #Pfizer

Evotec and Pfizer collaborate on metabolic and infectious diseases

Evotec and Pfizer have entered into a multi-year research collaboration, initially focused on early discovery research for metabolic and infectious diseases. The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics… Read More

#Business & Investment #News

A team working in a laboratory
#AI / data analytics / healthtech / informatics #Collaboration #Contract Research Organisations (CROs) #Drug discovery #Webinar

Connecting teams and designsets across the DMTA cycle

This paid-for advertorial by Cresset appeared in DDW Volume 25 – Issue 3, Summer 2024. Earlier this year, DDW hosted a webinar, ‘Enhancing collaboration in drug discovery – a biotech perspective’, supported by Cresset. The event emphasised the importance of creating a solid infrastructure within any discovery project to enable close… Read More

#Exclusive Content

siRNA
#Aptamer Group #Aptamers #AstraZeneca #Collaboration #Gene therapy #siRNA

AstraZeneca and Aptamer test liver delivery vehicles with siRNA

Aptamer Group and AstraZeneca have entered a collaboration agreement to evaluate Aptamer’s Optimer fibrotic liver delivery vehicles for the targeted delivery of small interfering RNA (siRNA). Following the encouraging results achieved to-date with Aptamer’s fibrotic liver delivery vehicles, the next phase of the research will explore the potential of the… Read More

#Business & Investment #News

#AI #Biomarkers #Clinical trials #Collaboration #Digital biomarkers #Nucleai #Precision medicine #Proscia

Proscia teams up with Nucleai to improve access to AI biomarkers

Software company Proscia has partnered with spatial AI biomarker company Nucleai in a collaboration aimed at improving precision medicine biomarkers for clinical trials.   The companies are integrating Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and will make them available as part of Proscia’s precision medicine AI portfolio.    The… Read More

#Business & Investment #News

Weight loss and obesity
#Collaboration #Flagship Pioneering #Obesity #Pfizer #ProFound Therapeutics

Breakthrough drug discovery research collaboration in obesity

Flagship Pioneering and ProFound Therapeutics have announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity. The collaboration is the first initiated under Flagship’s Pioneering Medicines strategic partnership with Pfizer announced in July 2023. Pioneering Medicines,… Read More

#News

T cell receptor
#Adaptimmune Therapeutics #Cell therapy #Collaboration #Galapagos #License agreement #Solid tumours

Companies partner on TCR T-cell therapy for head & neck cancer

Adaptimmune Therapeutics and Galapagos have entered into a clinical collaboration agreement to develop Adaptimmune’s TCR T-cell therapy for head and neck cancer and other potential solid tumours. Under the terms of the agreement, Adaptimmune will receive an upfront exclusivity payment of $70 million, plus $15 million… Read More

#Cancer Research #News

#Biomarkers #Collaboration #Dana-Farber Cancer Institute #OncoHost #Oncology

Companies partner to identify biomarkers for renal cell carcinoma

OncoHost and Dana-Farber Cancer Institute have launched a new study to identify biomarkers for renal cell carcinoma (RCC). Immune-checkpoint inhibitor (ICI) therapy has transformed treatment outcomes for RCC. However, ICIs can also trigger immune-related adverse events and may not benefit all patients. The collaboration… Read More

#Cancer Research #News

Biological materials logistics
#Atelerix #Collaboration #DefiniGEN #Human disease models #Logistics #Sustainability

New approach preserves biological materials without freezing

DefiniGEN and Atelerix have reached an agreement which combines DefiniGEN’s iPSC hepatocytes (Opti-Heps) with Atelerix’s hydrogel preservation technology. The companies report that they have been able to successfully ship in vitro liver models from the UK to the US. In vitro liver models can speed… Read More

#News

#Collaboration #Drug discovery #Partnership

Nine new industry collaborations driving drug discovery forward

1. SpyBiotech and the University of Oxford Biotechnology company SpyBiotech and University of Oxford have entered a research agreement for the development of a vaccine against Epstein-Barr virus (EBV). The project will combine Oxford’s academic research capabilities with SpyBiotech’s proprietary SPYVLP platform technology to advance three… Read More

#News

Francis Crick Institute
#Collaboration #Drug discovery #Francis Crick Institute #Research and development

UK academic-SME collaborations bring new tech to drug discovery

The Francis Crick Institute in the UK has announced the inception of six partnerships with small and medium-sized enterprises (SMEs), focussed on the application of novel technologies to discovery projects led by Crick researchers. The collaborations are supported by a Business Engagement Fund award from the… Read More

#News

#Bone disease #Collaboration #Heart disease #mRNA #Oncology #Partnership

This week in drug discovery (20-24 May) 

News round-up for 20-24 May by DDW Senior Digital Content Editor Diana Spencer. The headline news this week emphasises the importance of shared expertise and collaboration, whether that be between nations, companies or research institutions, to enable the greatest advances in drug discovery. The top stories:… Read More

#News

#Autoimmune disease #Collaboration #etherna #Hasselt University #Lipid based nanoparticle (LNP) #mRNA

Autoimmune mRNA therapeutics research collaboration 

etherna has entered a research collaboration with Hasselt University (UHasselt) to develop an mRNA based treatment for autoimmune disorders.   Funded by Flanders Innovation & Entrepreneurship (VLAIO), the project aims to combine etherna’s vast expertise in developing customised mRNA and lipid-based nanoparticle technologies for immuno-modulation with UHasselt’s research into autoimmune diseases… Read More

#Business & Investment #News

Human heart
#AI #AstraZeneca #BenevolentAI #Collaboration #Drug discovery #Heart failure #Target identification

AI collaboration shows success for novel heart failure target  

AstraZeneca has added a novel target for heart failure to its discovery portfolio through its collaboration with BenevolentAI.  This novel target for heart failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca. This is the first target to be selected from the extended… Read More

#News